Skip to content
DeepViews

ANI Pharmaceuticals, Inc. (ANIP) — 分析摘要

ANI Pharmaceuticals, Inc.(ANIP)的市值为1.70十亿美元,最近一年的营收同比增长了+43.8%。净利润率为8.9%。当前市盈率为15.7倍。

核心要点

  • 营收同比变化+43.8%
  • 净利润率8.9%
  • 市盈率15.7倍

与PHARMACEUTICAL PREPARATIONS板块的其他公司相比,ANIP的营收增长为+43.8%,市盈率为15.7倍。

[XNAS]

ANI Pharmaceuticals, Inc. (ANIP)

$73.59

前收盘价 2026-10-12 · 市场数据 POLYGON · 财务数据 SEC EDGAR

市值
$1697.28M
企业价值
$1638.55M
市盈率
15.7
股息率
0.00%
EV/EBITDA
6.9
公司简介
关于
关于 ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

行业

PHARMACEUTICAL PREPARATIONS

员工人数

970

总部

PRINCETON, NJ

Exchange

XNAS

官网
Source: Polygon.io
评分
竞争壁垒
竞争壁垒
52
窄护城河

基于 4 年财务数据的系统性竞争优势评估

此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。

市场信号
估值
盈利
内部人交易
内部人备案活动

首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。

加载 SEC 内部人备案数据...
超级投资者
财务健康
财务健康

资本结构

总权益$597.21M
总债务$301.48M
债务权益比0.50
现金及等价物$360.21M

现金流

经营现金流$189.47M
自由现金流$172.99M
自由现金流率17.68%
P/FCF 比率9.81
Source: Polygon.io · SEC EDGAR
股息
最新资讯
Recent News

免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。